Business Wire

WIKIFARMER

23.6.2022 10:02:13 CEST | Business Wire | Press release

Share
Wikifarmer Raises Large Seed Round From World Class Investors to Spread Sustainable Agricultural Knowledge Across the Globe and Digitize Agricultural B2B Commerce

Wikifarmer , a global platform with the mission of empowering farmers through educating them and offering them access to the open market to sell their products at fair prices and mentioned as the “Wikipedia of Farming” by the FAO of the UN, has successfully completed a Seed financing round with the support of a group of world class investors such as Mathias Kamprad, Inter IKEA BoD, Patrick and Cynthia Odier of the Lombard Odier Private Bank, Sophia Bendz, venture capitalist and former Spotify global director of marketing, Alexandre Vilgrain, C.E.O. of SOMDIAA group, the Constantakopoulos foundation and with the participation of Metavallon Venture Capital, a leading Greek VC firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005694/en/

Agriculture is still one of the least digitized industries in the world and this has not allowed the industry’s value chain to be disrupted, but instead has created a paradox; farmers are the most valuable part of agriculture’s value chain but make the least profit out of it. In addition to that, most farmers are still using the techniques of their ancestors to grow their crops. The need for up-to-date sustainable agriculture knowledge has never been greater in the world than today. Agriculture & food trade market is expected to exceed 6 trillion EUR in value by the end of 2025.

Wikifarmer’s platform allows farmers to access free up to date knowledge on agricultural best practices and gives them the opportunity to sell their products directly to businesses, helping them minimize or surpass the large number of intermediaries that currently exist. Wikifarmer is aiming to become the universal source for farmers searching for information and the go-to destination for people seeking to purchase agricultural products globally.

Co-founders Ilias Sousis, Peter Sagos and Harry Parianos were inspired by the negative impact that outdated practices in agriculture have on the environment, global hunger and the financial sustainability of farmers. At the same time, helping farmers make a higher profit margin out of their commercial activities will have a wider impact on the economy and on the quality of products produced.

Sousis has been a part of the management team of Google Greece for years, leading the commercial launch of YouTube in Greece and Cyprus and has had prior entrepreneurial experience in traditional commerce, while Sagos is a passionate agronomist with deep knowledge in agricultural production and a business background as he was running a seeds trading family business. Parianos is the owner and CEO of McCann Athens and has spent more than 30 years as a senior leader in the advertising industry.

Wikifarmer’s library and marketplace has already been visited by 12 million visitors from more than 200 countries while 30,000 products have been uploaded by farmers. More than 5,000 buyers - including food processing units (FMCGs, Food services, etc), Wholesalers/ Importers, Retail Stores and Hotels/Restaurants - have purchased a product directly from a farm.

The investment will be used to expand the educational content to 20 languages and to enhance Wikifarmer’s marketplace presence in Greece, Italy, France and Spain, with the objective to create a Mediterranean hub of farmers that will attract buyers from all over the world, establishing the platform in a leading place globally.

Sagos said: “We want to democratize agriculture, give farmers around the world the chance to learn new things and thus the opportunity to grow their capabilities, their crops, their earnings. This is the only way forward to make this sector more sustainable and feed the growing world population.”

Ilias Sousis, mentioned regarding the raise: “I am thrilled that a group of very important and sustainability-conscious world-class investors are sharing our vision and efforts to solve some of the biggest pain points that have troubled the sector of agriculture for hundreds of years now.”

Link:

ClickThru

Social Media:

https://www.facebook.com/Wikifarmer.official/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye